- DocumentoAn Introduction to Kinases and Kinase Inhibitorscargado porBiotech Investors' Database
- DocumentoLa Transformation d'Oncodesign ... à Paris-Saclaycargado porBiotech Investors' Database
- DocumentoOncodesign in Paris-Saclaycargado porBiotech Investors' Database
- DocumentoThe Big Picture For Genfit_NASH+diabetes+CVDcargado porBiotech Investors' Database
- DocumentoNo Doubt Genfit's Elafibranor cures Nashcargado porBiotech Investors' Database
- DocumentoNew Genfit Data Challenge Placebo-Positive and Elafibranor-Negative Biopsy Interpretationscargado porBiotech Investors' Database
- DocumentoL'Action Du GFT505 Sur Les Récepteurs Nucléaires PPARcargado porBiotech Investors' Database
- DocumentoCellectis Demonstrates Potential of Allogenic CAR-T Technologycargado porBiotech Investors' Database
- DocumentoThe Paradox of Obeticholic Acid for the Treatment of NASHcargado porBiotech Investors' Database
- DocumentoGFT505, Genfit's PPAR Agonist for the Treatment of NASHcargado porBiotech Investors' Database